Key Points
- BDX EVP Michael Feld sold 75 shares at an average price of $157.13, reducing his direct holdings by 0.36% to 20,934 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Becton Dickinson reported quarterly revenue of $4.71 billion and adjusted EPS of $2.90, exceeding analyst expectations, while revenue increased 5.2% year over year. The company issued FY 2026 EPS guidance of $12.52–$12.72.
- The company declared a quarterly dividend of $1.05, equivalent to an annualized $4.20 and a 2.5% yield. Analysts’ consensus rating is Hold, with an average price target of $180.93.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 75 shares of Becton, Dickinson and Company stock in a transaction on Monday, July 27th. The shares were sold at an average price of $157.13, for a total transaction of $11,784.75. Following the sale, the executive vice president directly owned 20,934 shares of the company's stock, valued at $3,289,359.42. This trade represents a 0.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Feld also recently made the following trade(s):
- On Friday, June 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $152.80, for a total value of $11,460.00.
- On Tuesday, May 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $147.35, for a total value of $11,051.25.
Becton, Dickinson and Company Trading Up 4.6%
NYSE:BDX opened at $166.21 on Wednesday. The company has a market capitalization of $45.80 billion, a P/E ratio of 42.08, a P/E/G ratio of 11.24 and a beta of 0.21. The stock's 50 day moving average price is $150.67 and its 200 day moving average price is $164.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same period in the previous year, the firm posted $3.35 earnings per share. The company's revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.5%. Becton, Dickinson and Company's dividend payout ratio is currently 106.33%.
Institutional Investors Weigh In On Becton, Dickinson and Company
Hedge funds and other institutional investors have recently made changes to their positions in the business. Crux Wealth Advisors lifted its position in shares of Becton, Dickinson and Company by 0.8% during the 4th quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier's stock worth $1,222,000 after purchasing an additional 49 shares during the last quarter. Larson Financial Group LLC boosted its stake in Becton, Dickinson and Company by 1.7% during the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier's stock valued at $627,000 after purchasing an additional 53 shares during the period. Camelot Portfolios LLC grew its holdings in Becton, Dickinson and Company by 1.5% in the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier's stock valued at $688,000 after buying an additional 54 shares during the last quarter. McElhenny Sheffield Capital Management LLC increased its position in Becton, Dickinson and Company by 3.6% in the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier's stock worth $309,000 after buying an additional 55 shares during the period. Finally, Atlantic Union Bankshares Corp increased its position in Becton, Dickinson and Company by 0.9% in the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier's stock worth $1,185,000 after buying an additional 57 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research firms have weighed in on BDX. Evercore set a $180.00 target price on Becton, Dickinson and Company in a report on Monday, July 6th. Stifel Nicolaus lowered their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Barclays raised their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an "overweight" rating in a research note on Monday, May 11th. The Goldman Sachs Group decreased their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating for the company in a research report on Wednesday, May 27th. Finally, Zacks Research upgraded Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a report on Friday, April 10th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus target price of $180.93.
View Our Latest Research Report on BDX
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
